TME Pharma NV
PAR:ALTME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TME Pharma NV
PAR:ALTME
|
DE |
Balance Sheet
Balance Sheet Decomposition
TME Pharma NV
TME Pharma NV
Balance Sheet
TME Pharma NV
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
2
|
4
|
2
|
1
|
4
|
1
|
10
|
9
|
5
|
2
|
3
|
|
| Cash Equivalents |
2
|
4
|
2
|
1
|
4
|
1
|
10
|
9
|
5
|
2
|
3
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
2
|
5
|
3
|
1
|
4
|
2
|
11
|
10
|
5
|
2
|
3
|
|
| PP&E Net |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
3
N/A
|
6
+95%
|
3
-52%
|
1
-68%
|
5
+386%
|
2
-62%
|
11
+516%
|
10
-8%
|
5
-46%
|
2
-52%
|
3
+37%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
2
|
3
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
1
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
3
|
3
|
2
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
1
|
0
|
0
|
2
|
1
|
3
|
4
|
1
|
0
|
|
| Total Current Liabilities |
5
|
7
|
5
|
4
|
7
|
4
|
3
|
5
|
6
|
3
|
2
|
|
| Long-Term Debt |
4
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
9
N/A
|
13
+40%
|
5
-59%
|
5
-10%
|
7
+47%
|
4
-50%
|
3
-18%
|
5
+79%
|
7
+24%
|
3
-57%
|
2
-36%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
0
|
2
|
2
|
10
|
0
|
0
|
1
|
2
|
0
|
1
|
|
| Retained Earnings |
102
|
118
|
129
|
135
|
147
|
148
|
158
|
173
|
188
|
194
|
200
|
|
| Additional Paid In Capital |
96
|
111
|
125
|
128
|
134
|
146
|
165
|
176
|
185
|
194
|
201
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
6
N/A
|
7
-13%
|
2
+65%
|
4
-58%
|
3
+34%
|
2
+29%
|
8
N/A
|
5
-41%
|
1
N/A
|
0
+77%
|
2
N/A
|
|
| Total Liabilities & Equity |
3
N/A
|
6
+95%
|
3
-52%
|
1
-68%
|
5
+386%
|
2
-62%
|
11
+516%
|
10
-8%
|
5
-46%
|
2
-52%
|
3
+37%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
17
|
94
|
|